:: Volume 10, Issue 4 (12-2021) ::
Int J Med Invest 2021, 10(4): 173-182 Back to browse issues page
Evaluation Of Cardiovascular Complications In Patients With COVID 19 Admitted In Two Teaching Hospitals In North Of Iran During Three Months
Narges Najafi , Mousa Javadian , Alireza Davoudi *
Associate Professor, Antimicrobial Resistance Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran
Abstract:   (1594 Views)
Background:  COVID-19 patients with cardiovascular underlying disease have more severe problems.
Methods and Materials: This is a retrospective descriptive-analytical cross-sectional study based on the information in patients' medical records. From March 2020 to the end of April, patients with COVID 19 hospitalized in Razi and Fatemeh Zahra teaching hospitals were included in the study.
Results: In this study, 1501 patients were evaluated. Patients ranged in age from 21 to 76 years with a mean and standard deviation of 54±18.4 which 766 cases (51.0%) were female. Forty cases (2.7%) developed a severe form of the disease, and 1461 cases (97.3%) had a mild form of COVID-19. The final diagnosis of a heart disorders was acute myocarditis in 5.7%, arrhythmia in 9.5% and myocardial infarction in 3.6% cases respectively, which also had a statistically significant difference between severe and mild groups P<0.0001.
Conclusion: Underlying cardiovascular diseases are associated with a higher severity in COVID-19 patients.
Keywords: COVID-19, Myocarditis, Myocardial Infarction, Arrhythmia
Full-Text [PDF 216 kb]   (429 Downloads)    
Type of Study: Research | Subject: General
References
1. 1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DS, Du B. ‎Clinical characteristics of coronavirus disease 2019 in China. New England journal of ‎medicine. 2020 Apr 30;382(18):1708-20.‎ ‎2. World Health Organization. Rolling updates on coronavirus disease (COVID-19) Updated ‎‎7 April 2020. (https:// www .who .int).‎ ‎3. Li T. Diagnosis and clinical management of severe acute respiratory syndrome ‎coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking :union: ‎Medical College Hospital (V2. 0) working group of 2019 novel coronavirus, Peking :union: ‎medical college hospital. Emerging microbes & infections. 2020 Jan 1;9(1):582-5.‎ ‎4. Gonzalez-Jaramillo N, Low N, Franco OH. The double burden of disease of COVID-19 in ‎cardiovascular patients: overlapping conditions could lead to overlapping treatments. ‎European journal of epidemiology. 2020 Apr;35(4):335-7.‎ ‎5. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. ‎The American journal of emergency medicine. 2020 Jul 1;38(7):1504-7.‎ ‎6. World Health Organization. COVID-19 clinical management: living guidance, 25 January ‎‎2021. World Health Organization; 2021.‎ ‎7. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory ‎syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. International ‎Journal of Infectious Diseases. 2016;49:129-33.‎ ‎8. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. ‎Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized ‎with COVID-19 in the New York City area. Jama. 2020;323(20):2052-9.‎ ‎9. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell LF, Chernyak Y, Tobin K, ‎Cerfolio RJ, Francois F, Horwitz LI. Factors associated with hospitalization and critical ‎illness among 4,103 patients with COVID-19 disease in New York City. MedRxiv. 2020 Jan ‎‎1.‎ ‎10. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, Satlin MJ, Campion Jr TR, ‎Nahid M, Ringel JB, Hoffman KL. Clinical characteristics of Covid-19 in New York city. ‎New England Journal of Medicine. 2020 Jun 11;382(24):2372-4. ‎ ‎11. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying ‎in relation to COVID-19 in Italy. Jama. 2020 May 12;323(18):1775-6.‎ ‎12. Stefanini GG, Montorfano M, Trabattoni D, Andreini D, Ferrante G, Ancona M, Metra ‎M, Curello S, Maffeo D, Pero G, Cacucci M. ST-elevation myocardial infarction in patients ‎with COVID-19: clinical and angiographic outcomes. Circulation. 2020 Jun ‎‎23;141(25):2113-6.‎ ‎13. CDC COVID-19 Response Team. Characteristics of Health Care Personnel with COVID-‎‎19 - United States, February 12-April 9, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr ‎‎17;69(15):477-481. doi: 10.15585/mmwr.mm6915e6. PMID: 32298247; PMCID: ‎PMC7755055. 14.‎ ‎14. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, ‎Zhao Y. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–‎infected pneumonia in Wuhan, China. Jama. 2020 Mar 17;323(11):1061-9. ‎ ‎15. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. ‎Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 ‎‎(COVID-19). JAMA cardiology. 2020 Jul 1;5(7):811-8.‎ ‎16. Shao F, Xu S, Ma X, Xu Z, Lyu J, Ng M, Cui H, Yu C, Zhang Q, Sun P, Tang Z. In-‎hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, ‎China. Resuscitation. 2020 Jun 1;151:18-23.‎ ‎17. Boyle JJ. Association of coronary plaque rupture and atherosclerotic inflammation. The ‎Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland. ‎‎1997 Jan;181(1):93-9.‎ ‎18. Naghavi M, Wyde P, Litovsky S, Madjid M, Akhtar A, Naguib S, Siadaty MS, Sanati S, ‎Casscells W. Influenza infection exerts prominent inflammatory and thrombotic effects on ‎the atherosclerotic plaques of apolipoprotein E–deficient mice. Circulation. 2003 Feb ‎‎11;107(5):762-8.‎ ‎19. Gattone M, Iacoviello L, Colombo M, Di Castelnuovo A, Soffiantino F, Gramoni A, ‎Picco D, Benedetta M, Giannuzzi P. Chlamydia pneumoniae and cytomegalovirus ‎seropositivity, inflammatory markers, and the risk of myocardial infarction at a young age. ‎American heart journal. 2001 Oct 1;142(4):633-40. ‎ ‎20.Sala S, Peretto G, Gramegna M, Palmisano A, Villatore A, Vignale D, De Cobelli F, ‎Tresoldi M, Cappelletti AM, Basso C, Godino C. Acute myocarditis presenting as a reverse ‎Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. European heart ‎journal. 2020 May 14;41(19):1861-2.‎ ‎21.Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A, Sepe PA, Resasco ‎T, Camporotondo R, Bruno R, Baldanti F. Myocardial localization of coronavirus in ‎COVID‐19 cardiogenic shock. European journal of heart failure. 2020 May;22(5):911-5.‎ ‎22. Kirkpatrick JN, Mitchell C, Taub C, Kort S, Hung J, Swaminathan M. ASE statement on ‎protection of patients and echocardiography service providers during the 2019 novel ‎coronavirus outbreak: endorsed by the American College of Cardiology. Journal of the ‎American College of Cardiology. 2020 Jun 23;75(24):3078-84.‎ ‎23. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 ‎‎(ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. ‎Intensive care medicine. 2020 Apr;46(4):586-90.‎ ‎24. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra ‎MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in ‎COVID-19. The Lancet. 2020 May 2;395(10234):1417-8.‎ ‎25. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic ‎risk. Arteriosclerosis, thrombosis, and vascular biology. 2003 Feb 1;23(2):168-75.‎ ‎26.Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with ‎glucocorticoid and human immunoglobulin. European heart journal. 2021 Jan 7;42(2):206.‎ ‎27.‎ Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, Cani DS, Cerini M, ‎Farina D, Gavazzi E, Maroldi R. Cardiac involvement in a patient with coronavirus disease ‎‎2019 (COVID-19). JAMA cardiology. 2020 Jul 1;5(7):819-24.‎ ‎28. Pelliccia F, Kaski JC, Crea F, Camici PG. Pathophysiology of Takotsubo syndrome. ‎Circulation. 2017 Jun 13;135(24):2426-41.‎ ‎29. Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular ‎disease: from basic mechanisms to clinical perspectives. Nature Reviews Cardiology. 2020 ‎Sep;17(9):543-58.‎ ‎30. Davoudi A, Najafi N, Aarabi M, Tayebi A, Nikaeen R, Izadyar H, Salar Z, Delavarian L, ‎Vaseghi N, Daftarian Z, Ahangarkani F. Lack of association between vitamin D ‎insufficiency and clinical outcomes of patients with COVID-19 infection. BMC Infectious ‎Diseases. 2021 Dec;21(1):1-7.‎ ‎31. Babamahmoodi F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Mousavi ‎SA, Ovaise G, Kordi S, Akbari Z, Azordeh M, Ahangarkani F, Alikhani A. Side effects and ‎Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health ‎care workers in Iran. Scientific Reports. 2021 Nov 2;11(1):1-8.‎ ‎32. Babamahmoodi F, Ahangarkani F, Alikhani A, Hatami M, Delavaryan L, Emadi S, ‎Nikseresht A. Comparing Clinical and Para-clinical Findings and Risk Factors among ‎COVID-19 Survived and Deceased Patients in North of Iran, 2019-2020. Journal of ‎Mazandaran University of Medical Sciences. 2021 Oct 10;31(201):70-82.‎


XML     Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 10, Issue 4 (12-2021) Back to browse issues page